Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement

Ronald C. Chen, R. Bryan Rumble, D. Andrew Loblaw, Antonio Finelli, Behfar Ehdaie, Matthew R. Cooperberg, Scott C. Morgan, Scott Tyldesley, John J. Haluschak, Winston Tan, Stewart Justman, Suneil Jain*

*Corresponding author for this work

Research output: Contribution to journalArticle

163 Citations (Scopus)
186 Downloads (Pure)

Abstract

Purpose: To endorse Cancer Care Ontario's guideline on Active Surveillance for the Management of Localized Prostate Cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines developed by other professional organizations. Methods: The Active Surveillance for the Management of Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the content and the recommendations. Results: The ASCO Endorsement Panel determined that the recommendations from the Active Surveillance for the Management of Localized Prostate Cancer guideline, published in May 2015, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the Active Surveillance for the Management of Localized Prostate Cancer guideline with added qualifying statements. The Cancer Care Ontario recommendation regarding 5-alpha reductase inhibitors was not endorsed by the ASCO panel. Recommendations: For most patients with low-risk (Gleason score ≤ 6) localized prostate cancer, active surveillance is the recommended disease management strategy. Factors including younger age, prostate cancer volume, patient preference, and ethnicity should be taken into account when making management decisions. Select patients with low-volume, intermediate-risk (Gleason 3 + 4 = 7) prostate cancer may be offered active surveillance. Active surveillance protocols should include prostate-specific antigen testing, digital rectal examinations, and serial prostate biopsies. Ancillary radiologic and genomic tests are investigational but may have a role in patients with discordant clinical and/or pathologic findings. Patients who are reclassified to a higher-risk category (Gleason score ≥ 7) or who have significant increases in tumor volume on subsequent biopsies should be offered active therapy.

Original languageEnglish
Pages (from-to)2182-2190
Number of pages9
JournalJournal of Clinical Oncology
Volume34
Issue number18
Early online date16 Feb 2016
DOIs
Publication statusPublished - 20 Jun 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement'. Together they form a unique fingerprint.

  • Cite this

    Chen, R. C., Bryan Rumble, R., Andrew Loblaw, D., Finelli, A., Ehdaie, B., Cooperberg, M. R., Morgan, S. C., Tyldesley, S., Haluschak, J. J., Tan, W., Justman, S., & Jain, S. (2016). Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. Journal of Clinical Oncology, 34(18), 2182-2190. https://doi.org/10.1200/JCO.2015.65.7759